Dramatic breakthrough in the war against cancer: the vaccine that has already passed a huge test
A personalized mRNA vaccine against melanoma succeeded in a Phase 3 trial, and now the technology is also being tested against lung and pancreatic cancer. The researchers hope that in the future, it will be…
Assessment
A personalized mRNA vaccine has cleared a Phase 3 trial against melanoma, marking a concrete step forward for cancer immunotherapy. The same platform is now being tested against lung and pancreatic cancers. If the technology scales as researchers hope, producing a custom vaccine for each patient within weeks could become standard practice. The real test is whether these early results hold across larger, more diverse patient populations.